|
Sartorius Stedim Biotech is a life science group providing solutions for the biopharmaceutical industry and research sector. The company supplies products and services for drug discovery, development, and biomanufacturing, covering the entire value chain from laboratory research to commercial production. Its portfolio includes single-use bag systems, bioreactors, process filtration, chromatography, cell culture media, and cell line development platforms. Key products and services include the CellCelector CLD Platform, Biosafe Rapid Transfer Port, and integrated bag systems for bioprocessing. The company serves customers in Europe, North America, and Asia, with manufacturing, R&D, and sales sites in these regions. Sartorius Stedim Biotech was established in 2007 through the merger of Stedim and the Biotech Division of Sartorius. Stedim was founded in 1978, originally focusing on parenteral nutrition bags before expanding into biotechnology. The group has expanded its portfolio through acquisitions, including Integrated Biosystems Inc. and Isolateur Dénominateur Commun, to offer integrated single-use technologies and aseptic transfer solutions. It partners with organizations such as Nibrt for training in intensified bioprocessing and supports diagnostic improvements through collaborations like the one with Jambo Labs in Tanzania. Summarised from the company's own disclosures, fiscal year ended Feb 2026 |
Industry Medical Instruments & Supplies | Homepage sartorius.com |
| Sector Healthcare | IR page sartorius.com/en/company/sartorius-ag-investor-relations | |
|
Tags
biopharmaceutical manufacturing, single-use systems, bioreactors, process filtration, cell culture media, cell line development, chromatography, aseptic transfer, life science research, biomanufacturing, CellCelector CLD Platform, Biosafe Rapid Transfer Port, Stedim, Integrated Biosystems Inc., Isolateur Dénominateur Commun, Nibrt, Jambo Labs, action medeo
|
Press page sartorius.com/en/company/newsroom |
Metrics
| Valuation | |
|---|---|
| Market cap | € 20.538B |
| Market cap (USD) | $ 23.031B |
| P/E | 77.33 |
| PEG | — |
| P/BV | 4.98 |
| P/S | 6.92 |
| P/OCF | 29.67 |
| P/FCF | — |
| Dividend yield | 0.33% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 6.5% |
| ROI | 4.4% |
| ROIC | 6.2% |
| Profit margin | 9.0% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | -32.8% |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | Yes |
| Buying back stock | No |
| Diluting (TTM) | Yes |
| Debt/Equity | 45.3% |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -17.6% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Balance sheet detail | |||||||
| Borrowings, current (EUR) | — | 13.1M | 25.5M | 4.5M | 57.7M | 39.5M | 557M |
| Borrowings, non-current (EUR) | — | 516M | 521M | 1.02B | 3.51B | 2.68B | 1.87B |
| Lease liabilities (EUR) | — | 58.3M | 78.9M | 111M | 115M | 146M | 175M |
| Cash and deposits (EUR) | 28.2M | 59.8M | 224M | 107M | 117M | 679M | 426M |
| Intangible assets (EUR) | — | 572M | 684M | 877M | 1.74B | 1.63B | 1.54B |
| Net debt (borrowings + leases - cash) (EUR) | — | 527M | 402M | 1.03B | 3.57B | 2.19B | 2.17B |
| Cash flow detail | |||||||
| Operating cash flow (EUR) | — | 417M | 696M | 612M | 746M | 815M | 692M |
| Change in receivables (cash effect) (EUR) | — | -73.9M | -87.3M | -65.8M | 162M | 38.3M | 42.9M |
| Change in inventories (cash effect) (EUR) | — | -117M | -275M | -218M | 131M | 208M | -46.4M |
| Change in payables (cash effect) (EUR) | — | 143M | 210M | -68M | -87.9M | 2.8M | -21.4M |
| Dividends paid (cash effect) (EUR) | — | -31.3M | -62.7M | -116M | -133M | -67.1M | -67.1M |
| Interest paid (cash effect) (EUR) | — | -8.06M | -8.26M | -10.3M | -117M | -177M | -154M |
| Income taxes paid (cash effect) (EUR) | — | -114M | -167M | -221M | -136M | -134M | -149M |
| Operating cash flow before change in receivables (EUR) | — | 491M | 783M | 678M | 584M | 777M | 649M |
| Income detail | |||||||
| Research and development expense (EUR) | — | 84.5M | 110M | 132M | 130M | 144M | 133M |
| ↳ 5y CAGR | +9.5% | ||||||
| Total comprehensive income (EUR) | — | 308M | 457M | 874M | 289M | 227M | 162M |
| Comprehensive income to owners (EUR) | — | 305M | 456M | 870M | 287M | 225M | 163M |
| Reported | Feb 16, 2022 | Feb 16, 2022 | Feb 16, 2022 | Feb 16, 2023 | Feb 15, 2024 | Feb 14, 2025 | Feb 16, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpRegulated information filed with the AMF (info-financiere.gouv.fr), newest first, titles as filed. Voting-rights totals, own-share transactions, threshold crossings and availability notices are left out. The link opens the filed document. Press releases from the company's own website, newest first.
Multimedia
In this section you will find press photos and footage material, presentations and publications, as well as the Sartorius logo for download.
[
\
Image/Video](https://www.sartorius.com/en/company/newsroom/multimedia-downloads#id-1193932)
[
\
Publications](https://www.sartorius.com/en/company/newsroom/multimedia-downloads#id-1176502)
[
\
Sartorius Logo](https://www.sartorius.com/en/company/newsroom/multimedia-downloads#id-16756)
Image and Video
Please note
These images are for editorial use only. If there are no references to the license terms of an image, you are requested to name Sartorius AG as the copyright owner. Pictures may not be modified or used for commercial purposes or advertising.
Executive Board Sartorius Group
March 04, 2026 | Chairman | CEO
Michael Grosse
JPEG | 7.7 MB
March 04, 2026 | CFO
Florian Funck
JPEG | 7.8 MB
March 04, 2026 | Bioprocess Solutions Division
René Fáber
JPEG | 8.3 MB
March 04, 2026 | Lab Products & Services Division
Alexandra Gatzemeyer
JPEG | 8.3 MB
Executive Board
JPEG | 8.2 MB | March 04, 2026
Locations
Sartorius Campus | Göttingen, Germany
JPEG 1.4 MB
Sartorius Campus | Göttingen, Germany
JPEG 903.0 KB
Sartorius Campus | Göttingen, Germany
JPEG 923.2 KB
Plant in Guxhagen, Germany
JPEG 2.3 MB
Plant in Ulm, Germany
JPEG 6.0 MB
Plant in Aubagne, France
JPEG 1.6 MB
US Headquarters | Bohemia, New York
JPEG 8.9 MB
Office building in Shanghai, China
JPEG 6.4 MB
Office Building | Beijing, China
JPEG 9.9 MB
Customer Interaction Center | Beijing, China
JPEG 1.5 MB
Plant in Yauco, Puerto Rico
JPEG 3.5 MB
Plant in Bangalore, India
JPEG 8.0 MB
Plant in Havant, United Kingdom
JPEG 653.1 KB
Plant in Beit Haemek, Israel
JPEG 2.2 MB
Plant in Adjovscina, Slovenia
JPEG 6.6 MB
Plant in M’Hamdia, Tunisia
JPEG 1.1 MB
Center of Excellence in Ann Arbor, USA
JPEG 679.2 KB
Plant in Illkirch, France
JPEG 1.7 MB
Integrated Solutions for the Manufacture of Biopharmaceuticals
Safety, flexibility and efficiency are playing an ever-increasing role in the manufacture of biopharmaceuticals. Configurable and scalable system solutions, such as Flexact®, can be used in all process steps – in preparation of media and buffers, cell harvesting, crossflow filtration, viral clearance, virus inactivation, polishing and in the form - fill and form - transfer process steps.
- Integrated Solutions JPEG | 4.1 MB | October 23, 2020
Process Development
The Ambr® 15 Microbioreactor Vessel determines optimal production conditions and is therefore an important tool for process development.
- Process Development JPEG | 3.7 MB | May 17, 2022
Analysis of Cell Culture Processes
Cell cultivation is initially tested at the lab-scale level. In trial series, the parameters of the individual samples are altered, such as pH, oxygen content and temperature, to find the conditions that are most conducive to optimal cell growth. During the cultivation process, the cultures are continually sampled and analyzed.
- Analysis of Cell Culture Processes JPEG | 5.0 MB | October 23, 2020
Safe Storage of Biologics
Transportation and storage of biologics are key intermediate steps in the production of biopharmaceuticals. To ensure the safety of these products across the entire process chain, these liquids are filled into sterile single-use bags and stored in specially designed tanks.
- Safe Storage of Biologics JPEG | 3.0 MB | May 10, 2022
Cell Cultivation in Biopharmaceutical Processes
To enable cells to grow optimally in the production of active pharmaceutical ingredients, cells are cultivated in a bioreactor under controlled conditions. Important factors for cell growth include the composition of the nutrient medium, mixing efficiency, temperature, dissolved oxygen saturation and pH.
- Cell Cultivation in Biopharmaceutical Processes JPEG | 3.7 MB | May 17, 2022
Label-Free Detection Systems for Biomolecular Interactions Analysis
Sartorius Octet® systems allow scientists to analyze molecular interaction in real time without the need for markers.
- Label-Free Detection Systems JPEG | 3.6 MB | May 06, 2022
Ultrapure Water in the Lab
Type I reagent-grade water is essential in any laboratory and is used in nearly every lab procedure. Whether used to clean laboratory glassware, to prepare buffers and cell culture media or to perform critical laboratory applications, such as DNA sequencing, ultrapure water must have the appropriate degree of purity in order to ensure reliable research results.
- Ultrapure Water in the Lab JPEG | 4.6 MB | October 23, 2020
Cell Harvesting
Sartoclear® depth filters were developed for demanding clarification applications in the biotechnological and pharmaceutical industries. The modular devices provide linear scalability from small to large scale processes.
- Cell Harvesting JPEG | 3.4 MB | May 06, 2022
Single-Use Filters
The preassembled Maxicaps® MR single-use filter configuration for the filtration of large volumes requires 90% fewer hoses and connections than comparable stainless steel systems.
- Single-Use Filters JPEG | 3.4 MB | May 06, 2022
Sartorius Video Loop
Download ZIP 220.1 MB
Sartorius Campus Video
Download ZIP 224.28 MB
Publications
Presentations Sartorius Group
Company Presentation Sartorius
PDF 2.4 MB
Investors Presentation
PDF 4.5 MB
Diversity Fact Sheet
PDF 2.0 MB
Other Publications
Annual Report 2025
PDF 11.6 MB
Universal Registration Document 2025
PDF 9.9 MB
Sartorius Press Kit (Logos, Annual Report, CEO Image, Product Images)
ZIP 28.3 MB
Insight | Sartorius in Profile
PDF 10.4 MB
Sartorius Campus | Directions
PDF 3.7 MB
Sartorius Campus | Sitemap
PDF 1.5 MB
Book Projects
PROCESS PEOPLE PRODUCT
Three renowned photographers explore the world of Sartorius in the three-part coffee-table book Process – People – Product.
Sartorius during the Third Reich
Professor Manfred Grieger researched and documented the activities of the company and its entrepreneurs during the Nazi era.
Too Big for the Old Works
Impressions, stories and pictures remind us of the old main plant, where Sartorius' heart beat for almost 120 years.
Sartorius 1870 - 2020
A team of authors examines the highs, lows, and technological advancements at Sartorius from a variety of viewpoints.
PROCESS PEOPLE PRODUCT
Three renowned photographers explore the world of Sartorius in the three-part coffee-table book Process – People – Product.
Sartorius during the Third Reich
Professor Manfred Grieger researched and documented the activities of the company and its entrepreneurs during the Nazi era.
Too Big for the Old Works
Impressions, stories and pictures remind us of the old main plant, where Sartorius' heart beat for almost 120 years.
Sartorius 1870 - 2020
A team of authors examines the highs, lows, and technological advancements at Sartorius from a variety of viewpoints.
PROCESS PEOPLE PRODUCT
Three renowned photographers explore the world of Sartorius in the three-part coffee-table book Process – People – Product.
Sartorius during the Third Reich
Professor Manfred Grieger researched and documented the activities of the company and its entrepreneurs during the Nazi era.
Follow Us on Social Media
[
\
LinkedIn](https://www.linkedin.com/company/15749)
[
\
Instagram](https://www.instagram.com/sartorius_group)
[
\
YouTube](https://www.youtube.com/user/SartoriusTV)
[
\
Facebook](https://www.facebook.com/sartoriusglobal/)
[
\
Glassdoor](https://www.glassdoor.com/Overview/Working-at-Sartorius-EI_IE264283.11,20.htm)
[
\
kununu](https://www.kununu.com/de/sartorius)
Sartorius Logo
Downloads
- Sartorius Logo - Media Essentials (PNG, SVG, PDF) ZIP | 1.5 MB | October 27, 2025
- Sartorius Logo - Print (PDF) ZIP | 1.1 MB | October 27, 2025
- Sartorius Logo - Digital (PNG) ZIP | 336.0 KB | October 27, 2025
Logo Usage Guidelines
How to Use the Logo | Clear Space, Sizes, and Colors
Placement
- Preferred positions: top-left or bottom-right.
- Choose the position that maximizes visibility and supports the layout. Keep the logo horizontal whenever possible.
Color options
Approved combinations:
- Black on Yellow (preferred)
- Black on White
- White on Black
- Do not use other colors, tints, or gradients. Ensure strong contrast for legibility.
Size and clear space
- Standard size: approximately one-third of the page including clear space.
- Always maintain ample clear space around the logo; keep text, images, or UI elements outside this area.
Don’ts
- Do not place the logo inside a small yellow box or any tight shape.
- Do not distort, rotate, recolor, or add effects (outlines, shadows, gradients).
- Do not place the logo on busy backgrounds that reduce readability.
Not Finding the Right Document?
If you can’t find a specific file, please contact Corporate Communications: [email protected]
Explore Sartorius
Company
Careers
Investor Relations
Company
General Information
Language & Regions
EN | Worldwide
Newsletter & Social Media
Sign Up for Newsletter
© 2026 Sartorius AG
Language Preference
Please select your country so we can show you products that are available for you.
Canada Germany United Kingdom United States Argentina Australia Austria Belgium Brazil Bulgaria China Croatia Cyprus Czech Republic Denmark Estonia Finland France Greece Iceland India Indonesia Ireland Italy Japan Latvia Lithuania Malta Mexico Netherlands New Zealand Norway Philippines Portugal Romania Singapore Slovakia Slovenia Spain Sweden Switzerland Worldwide
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.
EnglishDeutschFrançaisEspañolPortuguês中文 한국어 日本語Italiano
Save
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Sartorius Stedim Biotech S.A.
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| FMED | 2.56% | 5,800 | $ 1.32M | Aug 31, 2026 |
| MTRA | 2.15% | 15,555 | $ 3.001M | Jul 31, 2026 |
| QLTI | 1.30% | 16,903 | $ 3.848M | Aug 31, 2026 |
| GDOC | 0.54% | 467 | $ 106.324K | Aug 31, 2026 |
| FWD | 0.50% | 70,359 | $ 16.019M | Aug 31, 2026 |
| TOUS | 0.21% | 17,296 | $ 3.344M | Jul 31, 2026 |
| RINT | 0.12% | 805 | $ 167.034K | Jun 30, 2026 |
| DFAI | 0.02% | 15,954 | $ 3.934M | Nov 12, 2026 |
| AVSD | 0.02% | 279 | $ 68.592K | Nov 16, 2026 |
| NTSI | 0.02% | 471 | $ 97.791K | Jun 30, 2026 |
| DFSI | 0.02% | 859 | $ 211.796K | Nov 12, 2026 |
| DFIC | 0.01% | 6,682 | $ 1.648M | Nov 12, 2026 |
| AVDE | 0.01% | 4,744 | $ 1.166M | Nov 16, 2026 |
| DFAX | 0.01% | 3,836 | $ 945.808K | Nov 12, 2026 |